Humana Inc. (NYSE:HUM – Get Rating) gapped down before the market opened on Thursday after TheStreet downgraded the stock from a b rating to a c+ rating. The stock had previously closed at $513.28, but opened at $499.13. Humana shares last traded at $492.19, with a volume of 245,244 shares traded.
A number of other equities analysts have also commented on the stock. Cowen raised their price objective on shares of Humana from $547.00 to $647.00 in a research report on Monday, November 7th. Truist Financial lifted their target price on shares of Humana from $570.00 to $650.00 in a research note on Thursday, November 3rd. Royal Bank of Canada boosted their price objective on shares of Humana from $560.00 to $637.00 and gave the company an "outperform" rating in a research report on Thursday, November 3rd. JPMorgan Chase & Co. dropped their target price on shares of Humana from $630.00 to $625.00 and set an "overweight" rating on the stock in a report on Friday, January 6th. Finally, Cowen upped their price target on shares of Humana from $547.00 to $647.00 in a research note on Monday, November 7th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Humana has an average rating of "Moderate Buy" and an average price target of $608.75.
Get Humana alerts:Insider Buying and Selling at Humana
In other Humana news, CEO Bruce D. Broussard sold 7,000 shares of the firm's stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $531.92, for a total value of $3,723,440.00. Following the completion of the sale, the chief executive officer now owns 65,602 shares of the company's stock, valued at $34,895,015.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Timothy S. Huval sold 635 shares of Humana stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $497.71, for a total transaction of $316,045.85. Following the completion of the transaction, the insider now directly owns 4,968 shares in the company, valued at $2,472,623.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 7,000 shares of the business's stock in a transaction that occurred on Monday, December 12th. The shares were sold at an average price of $531.92, for a total value of $3,723,440.00. Following the completion of the sale, the chief executive officer now owns 65,602 shares of the company's stock, valued at $34,895,015.84. The disclosure for this sale can be found here. Insiders have sold 22,635 shares of company stock worth $11,565,286 over the last quarter. Insiders own 0.39% of the company's stock.
Institutional Trading of Humana
Large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Humana by 1.3% during the third quarter. Vanguard Group Inc. now owns 11,181,313 shares of the insurance provider's stock worth $5,425,061,000 after buying an additional 147,619 shares during the last quarter. FMR LLC lifted its stake in Humana by 0.6% during the 2nd quarter. FMR LLC now owns 6,753,633 shares of the insurance provider's stock worth $3,161,173,000 after acquiring an additional 40,087 shares in the last quarter. State Street Corp increased its holdings in Humana by 1.0% during the 3rd quarter. State Street Corp now owns 5,613,554 shares of the insurance provider's stock worth $2,728,012,000 after purchasing an additional 53,899 shares during the period. Bank of New York Mellon Corp increased its holdings in Humana by 63.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,692,255 shares of the insurance provider's stock worth $821,065,000 after purchasing an additional 654,681 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Humana by 0.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,126,002 shares of the insurance provider's stock worth $546,388,000 after purchasing an additional 5,926 shares during the period. 93.38% of the stock is currently owned by hedge funds and other institutional investors.Humana Trading Down 4.6 %
The company has a market cap of $62.00 billion, a PE ratio of 22.21, a P/E/G ratio of 1.30 and a beta of 0.72. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $511.66 and a two-hundred day simple moving average of $506.00.
Humana (NYSE:HUM – Get Rating) last announced its earnings results on Wednesday, February 1st. The insurance provider reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.46 by $0.16. The firm had revenue of $22.44 billion during the quarter, compared to analysts' expectations of $22.45 billion. Humana had a return on equity of 19.99% and a net margin of 3.07%. The business's revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.24 EPS. Analysts anticipate that Humana Inc. will post 25.05 EPS for the current year.
Humana Company Profile
(Get Rating)
Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts.
Featured Stories
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.